Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. - Wikidata - awgldk - TriplyDB

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.

http://www.wikidata.org/entity/Q34060110

about

Lupus Nephritis: A Different Disease in European Patients?Current and emerging treatment options in the management of lupus Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications Use of biologics in SLE: a review of the evidence from a clinical perspective Unmet medical needs in systemic lupus erythematosus What is new in the management of rapidly progressive glomerulonephritis?CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry.Prospective data collection of off-label use of rituximab in Australian public hospitals.Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.Novel therapeutic agents in clinical development for systemic lupus erythematosus.In-/off-label use of biologic therapy in systemic lupus erythematosus.Genetics of Lupus Nephritis: Clinical Implications.Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review.Ofatumumab treatment in lupus nephritis patients.Lupus nephritis in children - 10 years' experience.B-cell depletion in the treatment of lupus nephritis.Indications for use and safety of rituximab in childhood renal diseases.B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab.Rituximab treatment in lupus nephritis--where do we stand?Minimising steroids in lupus nephritis--will B cell depletion pave the way?B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.B-cell targeted therapeutics in clinical development.B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.Systemic lupus erythematosus: a therapeutic challenge for the XXI century.Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.Rituximab and lupus--a promising pair?Biologics in systemic lupus erythematosus: current options and future perspectives.Treatment of severe lupus nephritis: the new horizon.The multifaceted aspects of refractory lupus nephritis.Current role of rituximab in systemic lupus erythematosus.Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.Reviewing the recommendations for lupus in children.Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.

P2860

Q26740483-6F6C2552-7A50-4B43-A294-E182C96D81E0 Q26741266-7B90C8A0-AE62-400E-9751-BF34C030F584 Q26775756-753B0F10-11E8-4E12-8B9A-4CDC749ACD68 Q26783652-849B6D3E-EB81-4C77-8A02-B4F1425C739E Q27005906-D2A468C5-6DD2-4167-80FE-6DC267B8A353 Q28259540-08182925-FCF6-4A59-A276-22C2848C2813 Q30388433-9720F9C2-BE5D-41B3-80D5-D0295CCCD152 Q30582614-C55D90BC-5A60-4C63-8FA6-1FA4519C984E Q30640279-991723F9-7B4E-49DC-AF61-F689A7649829 Q33885872-D7E15F55-9DC1-425E-9493-82DAC3CC9D77 Q34704902-BDE92479-6FF6-4CA7-9CB7-64406BEC8619 Q35094536-B3E47FAB-68EF-4748-86BD-6E8199397447 Q36300008-F4721E65-2E70-4FC3-9C8C-8717EC9A1586 Q36302245-7D557D1F-A7D1-44C4-892A-81790E13A526 Q36469965-EE963404-8749-47B4-8092-5CCBAFE82477 Q36518986-220851AC-5268-4C94-AE3C-D62DB399EB58 Q36981769-71E24E8C-EEDF-4AAD-9B77-1351C9B50E63 Q37119045-BA0D11C3-9B18-4ED1-A769-D439C60405D3 Q37399315-91109D3D-CC03-44AA-8AF8-2E177AE877C9 Q38026784-250E467E-B942-48BC-A5FC-A74FFEBD56A4 Q38044851-245D15AB-61AC-4A8A-8ADC-03DFEB482C97 Q38051302-1EBE27CB-6BFD-4774-A07F-FD295B7C37B5 Q38095863-41A24F79-8290-48B4-92EA-D7549DDE8275 Q38095864-6C3B54A0-6929-4D2B-80BC-BED86147ED47 Q38097129-1D63D154-FE5D-4946-95EE-24DFBC0CF25E Q38097162-0A0CB5D9-E353-48AE-8471-7B4C0AA357BB Q38131034-336DB1C2-79F7-46A6-98DD-61477A9133C9 Q38150110-73FAC118-9541-40E7-B4F3-3856281C47C6 Q38154934-355E8846-39BE-47D1-BAFA-C9266936C6A2 Q38191835-2B861E3A-2251-440C-9FCA-1AAD5078DF6E Q38192656-7FFF3FA5-7B3D-431B-85D5-A92184576269 Q38192683-DD98A675-4C85-4419-B2D0-5C3B44067F93 Q38235185-8680136A-1654-4889-9008-9E9A43DEEBF3 Q38238798-FEF66FA6-CA69-48AB-9E53-9AEB46D98756 Q38271125-21FE350A-675A-4417-8BB4-91FBF17BC3C8 Q38285375-254B0EFA-61F7-466B-A8F4-733BAF792D04 Q38293284-3D3A4979-B16C-4A99-BD0F-F45219D406A4 Q38306720-E60D6CCE-295C-4E05-BAFC-B40EDECB32F4 Q38374309-BDABD3E2-5A4C-4A94-A4DF-4C365F33DAC9 Q38389307-CF58C29E-794A-4E65-A9D2-DBA53411F03F

P2860

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.

http://www.wikidata.org/entity/Q34060110

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@ast

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@en

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@en-gb

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@nl

type

label

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@ast

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@en

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@en-gb

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@nl

prefLabel

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@ast

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@en

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@en-gb

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@nl

P1433

Q34060110-A10D00A2-8327-4BFC-B263-AF604417EE0F

P1476

Q34060110-C48FDE96-1BE2-47BE-AFA9-5E46B107F69F

P2093

Q34060110-28BBBEBE-2385-452A-9E61-ADB15586E9B2

Q34060110-4D7166AE-2B9B-477A-B28A-24E62981EC90

Q34060110-50452FBB-A8A6-4699-8D31-3AF5C2A82B17

Q34060110-6AB45518-5B7D-43E4-BE3A-70D4A8A9FB72

Q34060110-7B266330-C7DE-4F10-B268-C4346458B381

Q34060110-8551D67F-E0D9-4470-932F-7827B7DD398D

Q34060110-9C987A87-9230-402B-A5E3-84732846BEA1

Q34060110-A7CBED39-E898-4A1B-AC92-84344EB3FE91

Q34060110-B65F5E4F-43CD-43C3-841F-BCD771E0487F

Q34060110-C19819D3-B702-409F-891D-76E93E8C0CD5

P304

Q34060110-26AE43C4-FB84-47FC-B905-075BDCB60285

P31

Q34060110-1203A218-CD5A-4B46-8049-0C275D4C6EED

Q34060110-19309096-3500-456e-a58a-fe7c1daec0f6

P356

Q34060110-027A4257-09F3-48BA-BD73-DD40B7D793C6

P433

Q34060110-4CC4CF44-0198-49DE-A41A-0D5F4471A9D6

P478

Q34060110-35655072-6A58-4EFE-9150-32D73DCD3EA9

P50

Q34060110-3331730F-4DA9-4580-A929-C4FB2B205907

Q34060110-CB354908-D9BC-4967-9434-AA08E72E61CB

Q34060110-CF86253D-F703-4D4F-9928-FBBF29C8298F

Q34060110-EA9BB0D4-57A4-4D49-AC47-C2B371BD6232

Q34060110-EC835D28-9CB3-4042-9394-6FAA170A6635

Q34060110-F05610C2-358B-4C3E-B32A-58185C89C9A6

Q34060110-F5B0C4BF-A557-4923-8406-6BC50EEAB138

P577

Q34060110-88B7BECC-D8D9-4C71-AB03-E838AB47FBD4

P6179

Q34060110-96B8D606-9A52-4829-87BF-0FAF8E882106

P698

Q34060110-3D217260-975F-44FD-AC75-4BB04A336BE4

P921

Q34060110-B0E3636E-4629-4C96-9AFD-5B373403AF98

P356

J.AUTREV.2011.10.009

P1433

Autoimmunity Reviews

P1476

Efficacy of rituximab in 164 p ...... ed data from European cohorts.

@en

P2093

Agustín Martínez-Berriotxoa

http://www.w3.org/2001/XMLSchema#string

Cándido Díaz-Lagares

http://www.w3.org/2001/XMLSchema#string

David D'Cruz

http://www.w3.org/2001/XMLSchema#string

David Jayne

http://www.w3.org/2001/XMLSchema#string

Edward M Vital

http://www.w3.org/2001/XMLSchema#string

Fausta Catapano

http://www.w3.org/2001/XMLSchema#string

Francisco García-Hernández

http://www.w3.org/2001/XMLSchema#string

Javier Rascón

http://www.w3.org/2001/XMLSchema#string

José-Luis Callejas-Rubio

http://www.w3.org/2001/XMLSchema#string

Sara Croca

http://www.w3.org/2001/XMLSchema#string

P304

357-364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AUTREV.2011.10.009

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Guillermo Ruiz-Irastorza

David A. Isenberg

Manuel Ramos-casals

Edward Marc Vital

Munther A. Khamashta

P577

2011-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034872285

http://www.w3.org/2001/XMLSchema#string

P698

22032879

http://www.w3.org/2001/XMLSchema#string

P921